Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Gold Price Hits Two-Month High as Investors Await US Inflation Data
US Judge Dismisses Gautam Adani Criminal Charges
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
Asian Currencies Steady as Markets Await U.S. Inflation Data
South Korean Won Leads Asian FX Losses as Dollar Rises
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Bets
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist
Shein Scales Back Vietnam Operations as US Trade Rules Shift
BOJ Signals Faster Rate Hikes as Inflation Risks Raise September Move Odds
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 



